helter-skelter [RSABE / ABEL]

posted by Mikalai  – Belarus, 2020-02-10 16:10  – Posting: # 21157
Views: 5,311

(edited by Mikalai on 2020-02-11 10:21)

Dear Helmut
There are some additional questions

» I cannot reproduce your numbers. Given.

My calculation was that I assumed that CV is 34 but we braced ourselves for the worst scenario. Am I correct that the worst scenario is around 42 subjects to compensate for TIE at CV 30% and 7(15%) subjects to compensate for a dropout rate?

PS
Total sample size 49

I assume that the TIE calculation is done after we have got our results from the sample. Is this calculation is straight forward with no other statistical approaches that may bring different results?

I guess that the TIE calculation and compensation for TIE correction were realized in PowerTost. What about validation issues? Any feedback from regulators on software?

How should we proceed if CV from our sample is 30.00%?

Should we calculate TIE if CV is less than 30% (I guess no)?

Has anyone submitted an ABEL trial with TIE correction and has got no objections from European regulators or FDA (Is this applicable for FDA?).

» Include the group term in the model (i.e., specify the FDA’s Model II taking into account that groups were tested on different dates) but without a pre-test. The loss in power is very, very low compared to the pooled Model III.

Can the use of Model 2 (FDA), basically group and its interactions, be a reason to reject study in Europe? Or it is a more conservative model and if we pass with this model we always pass with the standard ABE model?

Best regards

Complete thread:

Activity
 Admin contact
20,477 posts in 4,300 threads, 1,415 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 22:51 CEST

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5